IQVIA (IQV) delivered solid Q1 FY2026 results with revenue growing 8.4% YoY to $4.15B and net income rising 10.0% to $274M, though operating margin compressed slightly to 12.4% amid elevated debt levels and aggressive share buybacks.
Key risk: High Leverage and Rising Long-Term Debt
Long-term debt stands at $14.0B as of Q1 FY2026, up 6.7% YoY, resulting in a debt-to-equity ratio of 3.75x. This elevated leverage increases interest expense burden and limits financial flexibility, particularly in a higher-for-longer interest rate environment.
Other Life Sciences Tools & Services companies